Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Daily capsule for patients with skin cancer

Patients with a rare form of skin cancer could now benefit from first-of-a-kind once daily capsule


Erivedge® (vismodegib), a new medicine that has been shown to help patients with a disfiguring and potentially life-threatening form of skin cancer, is now registered for use in New Zealand.

Erivedge is a first-in-class Hedgehog Pathway Inhibitor that helps shrink disfiguring or potentially life-threatening lesions in advanced skin cancer

AUCKLAND – 23 April 2014: From today, adult New Zealanders with metastatic basal cell carcinoma (mBCC) or locally advanced BCC (laBCC) where treatment with surgery or radiotherapy is inappropriate, could benefit from Erivedge®. 1 This makes Erivedge, a capsule taken once daily, the only registered medicine for advanced BCC (aBCC, is comprised of mBCC and laBCC) fulfilling an unmet medical need in this group of patients.1

BCC is the most common type of skin cancer in the world. 2 It is estimated that in 2006 there were 43,900 New Zealanders diagnosed with BCC and that this number is growing year on year.

BCC forms the majority (65% - 75%) of non-melanoma skin cancers (NMSC). In 2006, NMSC was estimated to have incurred NZ$51.4 million in healthcare costs (excluding GST) and NZ$6.7 million in lost production.

BCC is considered curable when confined to the skin.

However, in some cases the disease will invade surrounding tissue (locally advanced) or spread to other parts of the body (metastatic BCC) in a manner that cannot be effectively treated with surgery or radiation.
Dr Richard Martin, Cutaneous Surgical Oncologist, says that advanced basal cell carcinoma can be highly disfiguring and can significantly impact quality of life.

“Until now, there have not been any active treatment options available for patients who are not appropriate for surgery or radiotherapy. Erivedge, which has been shown to shrink tumours, addresses this unmet need and is a welcome new treatment option for patients with advanced BCC,” said Dr Martin.

An independent review facility assessment found that Erivedge shrank visible lesions in 43 percent (27/63) of patients with locally advanced BCC inappropriate for surgery or radiotherapy and shrank tumours in 30 percent (10/33) of those with metastatic BCC.

An application for funding will be submitted to PHARMAC in due course. In the interim, Erivedge will be available for private purchase .

-ENDS-

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Half Full: Dairy Payouts Steady, Cash Will Be Tight

Industry body DairyNZ is advising farmers to focus on strong cashflow management as they look ahead to the 2015-16 season following Fonterra's half-year results announcement today. More>>

ALSO:

First Union: Cotton On Plans To Use “Tea Break” Law

“The Prime Minister reassured New Zealanders that ‘post the passing of this law, will you all of a sudden find thousands of workers who are denied having a tea break? The answer is absolutely not’... Cotton On is proposing to remove tea and meal breaks for workers in its safety sensitive distribution centre. How long before other major chains try and follow suit?” More>>

ALSO:

Scoop Business: NZ-Korea FTA Signed Amid Spying, Lost Sovereignty Claims

A long-awaited free trade agreement between New Zealand and South Korea has been signed in Seoul by Prime Minister John Key and the Korean president, Park Geun-hye. More>>

ALSO:

PM Visit: NZ And Viet Nam Agree Ambitious Trade Target

New Zealand and Viet Nam have agreed an ambitious target of doubling two-way goods and service trade to around $2.2 billion by 2020, Prime Minister John Key has announced. More>>

ALSO:

Scoop Business: NZ Economy Grows 0.8% In Fourth Quarter

The New Zealand economy expanded in the fourth quarter as tourists drove growth in retailing and accommodation, and property sales increased demand for real estate services. More>>

ALSO:

Scoop Business: RBNZ’s Wheeler Keeps OCR On Hold, No Rate Hikes Ahead

The Reserve Bank has removed the prospect of future interest rate hikes from its forecast horizon as a strong kiwi dollar and cheap oil hold down inflation, and the central bank ponders whether to lower its assessment of where “neutral” interest rates should be. The kiwi dollar gained. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news